title: Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.
abstract: OBJECTIVE
  Interferon-alfa-based therapy is effective in the treatment of Hepatitis C. However, some patients fail to respond and others relapse, after initially responding. Our objective was to assess the efficacy, safety and predictive factors for sustained virological response (SVR) to peginterferon plus ribavirin in chronic hepatitis C patients who failed to interferon-alfa (IFNα)-based therapy.
  
  
  METHODS
  Seventy-five consecutive patients who failed to IFNα-based therapy were retreated with peginterferon plus ribavirin. Of these patients, 85% were infected by genotype 1. The primary endpoint was SVR.
  
  
  CONCLUSIONS
  Of 75 non-responder (n = 54) or relapser patients (n = 21), 50 were previously treated with IFNα-monotherapy and 25 with IFNα plus ribavirin. Global SVR rate was 41.3%: for patients re-treated with IFNα the response was 48% whilst for those retreated with IFNα plus ribavirin, it was 28%. For previous non-responders the SVR rate was 37% and for relapsers it was 52.4%.
  
  
  CONCLUSIONS
  Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non-responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously.
authors.affiliation: Gastroenterology and Hepatology Service, Hospital Universitario de La Princesa, Autonomous University of Madrid, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. mtraperomarugan@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Trapero-Marugán
authors.forename: J
authors.initials: J
authors.lastname: Mendoza
authors.forename: J A
authors.initials: JA
authors.lastname: Moreno Monteagudo
authors.forename: M
authors.initials: M
authors.lastname: Chaparro
authors.forename: L
authors.initials: L
authors.lastname: García-Buey
authors.forename: L
authors.initials: L
authors.lastname: González-Moreno
authors.forename: M J
authors.initials: MJ
authors.lastname: Borque
authors.forename: R
authors.initials: R
authors.lastname: Moreno-Otero
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a